In a groundbreaking study published in Molecular Cell, researchers at NYU Langone Health have uncovered a novel mechanism by which cancer cells harboring abnormal chromosome numbers evade the lethal effects of treatments. This discovery sheds new light on the role of aneuploidy—where cells possess either extra or missing chromosomes—in promoting cancer cell resistance, offering promising avenues for future therapeutic interventions.
Chromosomes, the organized bundles of DNA strands within cells, carry the essential genetic instructions that govern cellular behavior. In healthy cells, tightly regulated processes ensure that chromosome numbers are precisely maintained during cell division. However, the unchecked, rapid proliferation characteristic of tumors often results in chromosome missegregation. This leads to aneuploidy, a condition previously correlated with heightened tumor aggressiveness but whose mechanistic underpinnings in therapy resistance remained elusive.
The NYU Langone team approached this challenge by engineering human colon, lung, and eye cell models with induced chromosome abnormalities. Upon exposing these aneuploid cells to reactive oxygen species (ROS)—highly reactive molecules known to inflict severe oxidative DNA damage—they observed a striking survival advantage compared to normal, chromosomally stable cells. This enhanced resilience appeared independent of whether chromosomes were gained or lost, highlighting a fundamental survival strategy employed by chromosomally aberrant cancer cells.
Delving deeper, researchers focused on the protein Poly (ADP-Ribose) Polymerase 1 (PARP1), a key enzymatic player in the DNA damage response pathway. Typically, PARP1 facilitates DNA repair but triggers cell death when DNA damage, such as that induced by oxidative stress, becomes overwhelming. Remarkably, aneuploid cancer cells were found to harbor 50 to 60 percent less PARP1 protein than their euploid counterparts. This deficiency essentially clamps down on the cell’s self-destruct mechanism, enabling damaged cancer cells to survive and propagate despite therapeutic assaults.
Addressing the molecular control behind this phenomenon, the team employed an advanced genome-wide CRISPR screen. This unbiased, systematic gene editing technique pinpointed that lysosomal stress—a disruption in the cell’s recycling centers—activates CCAAT/enhancer-binding protein beta (CEBPB). This transcription factor then suppresses PARP1 gene expression, further dampening cell death pathways. This intricate signaling axis reveals how chromosome missegregation indirectly rewires gene regulation to favor cancer cell survival.
Mouse models provided compelling functional evidence as well. Lowering PARP1 levels enhanced metastatic spread, allowing cancer cells to colonize distant organs more efficiently. Conversely, restoring PARP1 expression curtailed this invasive capability. These preclinical results were corroborated by clinical data, which demonstrated significantly reduced PARP1 levels in metastatic colorectal tumors compared to their primary tumor origins.
This new insight reframes our understanding of aneuploidy’s role in cancer pathology. It not only fuels tumor growth but actively rewires cellular stress responses to evade oxidative damage-induced death. Consequently, these findings suggest that therapeutic strategies aimed at restoring PARP1 function, or targeting key nodes of the lysosomal stress response, could dismantle this survival advantage, limiting cancer progression and metastasis.
The study’s senior author, Dr. Teresa Davoli, emphasizes the significance of these findings: “By illuminating how aneuploidy contributes to both tumor proliferation and metastatic behavior through PARP1 suppression, we open new therapeutic possibilities targeting these pathways.” The collaborative effort included scientists from various domains within NYU Langone Health’s Institute for Systems Genetics and Perlmutter Cancer Center, underscoring the interdisciplinary nature of this breakthrough.
Looking ahead, the research team is keen to investigate how this aneuploidy-driven PARP1 reduction influences responsiveness to existing cancer drugs, particularly PARP inhibitors which are already deployed clinically. Their initial observations suggest that aneuploid tumors might display unique vulnerabilities or resistances to these agents, which could inform precision medicine approaches moving forward.
Importantly, these revelations come amidst a broader quest to understand the genetic and molecular diversity of cancers. Aneuploidy is a hallmark of many malignancies, yet its functional consequences have remained enigmatic. By unraveling how chromosomal errors shift the balance between cell death and survival, this study provides a pivotal piece in the cancer puzzle, potentially sparking innovative drug development pipelines designed to exploit these vulnerabilities.
This comprehensive research was supported by multiple esteemed funding bodies including the National Institutes of Health, Cancer Research UK, and the Mark Foundation for Cancer Research. The convergence of cutting-edge experimental methods, rigorous genetic screening, and translational mouse models illustrates the paradigm of modern biomedical research advancing cancer biology.
As the landscape of cancer therapeutics evolves, understanding the interplay between chromosomal instability and cellular signaling pathways will be key to overcoming resistance mechanisms. The discovery that aneuploidy-induced PARP1 suppression significantly drives oxidative stress resistance underscores this intricate interplay, promising to reshape future strategies for combating resistant and metastatic cancers.
Subject of Research: Cells
Article Title: Molecular Cell PARP1 Suppression Drives ROS Resistance in Aneuploid Cancer Cells
News Publication Date: 7-May-2026
Keywords: Cancer cells, Aneuploidy, Chromosome abnormalities, PARP1, Oxidative stress, Reactive oxygen species, Cell death, Lysosomal stress, CEBPB, Metastasis, DNA damage response, CRISPR screen
